乳腺癌内分泌治疗与骨保护进展1 2022/6/7内容 LBA500：NSABP B-35关于绝经后DCIS采取“肿块切除+放疗” 常规治疗基础上，内分泌治疗选择TAM和阿那曲唑何者更优？1 A501：CALGB40503关于绝经后激素受体阳性乳腺癌一线选择来曲唑单药或联合贝伐单抗的期临床研究；234LBA502：PALOMA3是对于激素受体阳性晚期乳腺癌内分泌解救选择氟维司群500mg基础加或不加CDK4/6抑制剂palbociclib的期临床研究；A503-504：早期乳腺癌辅助双膦酸盐或地诺单抗（denosumab）治疗期临床研究(S0307和ABCSG-18);2 2022/6/7Slide 35Presented By Eric Winer at 2015 ASCO Annual Meeting3 2022/6/7Slide 37Presented By Eric Winer at 2015 ASCO Annual Meeting主要研究终点：BCFI4 2022/6/7Slide 38Presented By Eric Winer at 2015 ASCO Annual Me
